Navigation Links
Pharmasset to Webcast an Investor Event from the AASLD Meeting
Date:10/27/2010

PRINCETON, N.J., Oct. 27 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS) today announced that it will webcast an investor event from the American Association for the Study of Liver Diseases (AASLD) on Sunday, October 31, 2010 starting at 7:00pm ET. During this webcast, management will review Pharmasset's progress on the programs that are the subject of presentations at AASLD.To access a simultaneous webcast of this event via the internet, log on to the "Events & Presentations" section of the Investor Center on Pharmasset's website at http://investor.pharmasset.com/events.cfm . Please connect to the website at least ten minutes prior to the start of the presentation to ensure adequate time for a reliable connection and any software download that may be necessary for the webcast.

The following abstracts are available on the AASLD website (AASLD.org).

RG7128Abstract 81"High rates of early viral response, promising safety profile and lack of resistance related breakthrough in HCV GT 1/4 patients treated with RG7128 plus PegIFN alfa-2a (40KD)/RBV: Planned Week 12 interim analysis from the PROPEL study" will be presented in the HCV Clinical Trials session on Sunday October 31st at 5:15pm ET. Authors of the study are Jensen, D. M. et al.

Abstract 799"No evidence of drug resistance or baseline S282T resistance mutation among GT1 and GT4 HCV infected patients on nucleoside polymerase inhibitor RG7128 and Peg-IFN/RBV combination treatment for up to 12 weeks: Interim analysis from the PROPEL study" will be presented in a poster session on Sunday October 31st. Authors of the study are Le Pogam, S. et al.

PSI-7977Abstract 806"High Rapid Virologic Response (RVR) with PSI-7977 Daily Dosing plus PEG-IFN/RBV in a 28-day Phase 2a Trial" will be presented in a poster sessi
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Pharmasset to Present at the JMP Healthcare Conference
2. Pharmasset to Present at the UBS Global Life Sciences Conference
3. Pharmasset Initiates Phase 2b Clinical Trial of PSI-7977 for Chronic Hepatitis C Genotypes 1, 2, and 3
4. Pharmasset to Present at the 28th Annual JPMorgan Healthcare Conference
5. Pharmasset Reports Fiscal Year End 2009 Financial Results
6. Pharmasset Announces the Continued Enrollment of the Phase 2b Clinical Trial of RG7128 for the Treatment of Hepatitis C
7. Pharmasset to Present at Lazard Capital Markets Healthcare Conference
8. Pharmasset Reports Positive Preliminary Antiviral Data With PSI-7851 for the Treatment of Hepatitis C
9. Pharmasset to Present at Goldman Sachs and Needham Healthcare Conferences
10. Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C
11. Pharmasset Voluntarily Halts Clinical Studies with Clevudine in Hepatitis B Infected Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... 31, 2015 Egalet Corporation (Nasdaq: ... company focused on developing, manufacturing and marketing innovative ... previously announced underwritten public offering of 7,666,667 shares ... price of $11.25 per share. The shares of ... issued upon the exercise in full by the ...
(Date:7/31/2015)... , July 31, 2015 According ... Market by Product (Bioimpedance Analyzers (BIA), Dual-Energy X-ray Absorptiometry ... Weighing) - Global Analysis & Forecast to 2019", published ... pegged at $911.1 Million 2014 and is estimated to ... CAGR of 9.4% from 2014 to 2019. ...
(Date:7/30/2015)... SAN DIEGO , July 30, 2015 ... announced it has signed a definitive agreement ... provider of non-invasive ventilation and sleep-disordered breathing ... strong clinical, innovation and market reputation in China, combined with ResMed,s global leadership ... of people in China ...
Breaking Medicine Technology:Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 2Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 3Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 4Body Composition Analyzers Market Worth $1,425.7 Million by 2019 2Body Composition Analyzers Market Worth $1,425.7 Million by 2019 3Body Composition Analyzers Market Worth $1,425.7 Million by 2019 4ResMed Invests in High-Growth Chinese Sleep and Respiratory Care Market with Curative Medical 2ResMed Invests in High-Growth Chinese Sleep and Respiratory Care Market with Curative Medical 3
... Japan, June 23 Although previous studies,suggest that ... of the eye in children with progressing myopia, ... Using a rigorous study design,and precise optical measuring ... Madrid are undertaking the Myopia Control with,Orthokeratology contact ...
... According to new data from,PAREXEL International Corporation (Nasdaq: ... the number of new,industry-sponsored clinical trial initiations, or ... in 2007. PAREXEL,s analysis shows that the,biopharmaceutical industry ... support of new clinical studies for drugs in,2007, ...
Cached Medicine Technology:Menicon Undertakes With the Novovision Clinic a Paediatric Myopia Control Clinical Trial 2PAREXEL Data Reveal A Record High Number of Clinical Trials Initiated 2PAREXEL Data Reveal A Record High Number of Clinical Trials Initiated 3PAREXEL Data Reveal A Record High Number of Clinical Trials Initiated 4PAREXEL Data Reveal A Record High Number of Clinical Trials Initiated 5
(Date:7/31/2015)... ... July 31, 2015 , ... The Radiology Business Management ... MD, (R-Tex) presenting “What’s Next for Health Care: A View From Capitol Hill” on ... of the Congressional Health Caucus, Rep. Burgess has a special understanding of the real ...
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... “ Crack’em ... the latest and coolest technology products available to consumers. Amanda Forstrom, a technology expert ... tool helps chefs make less mess while cooking. , Cooking can be a very ...
(Date:7/31/2015)... Louis, MO (PRWEB) , ... July 31, 2015 , ... ... currently underway in U.S. District Court in the Northern District of Illinois, Androgel testosterone ... On Monday, July 20, a docket entry was made recording the minutes of the ...
(Date:7/31/2015)... ... ... Seals Southern Georgia’s Heels & Wheels Duathlon & Triathlon will be held Saturday, August 22nd ... duathlon is a 2 mile run, 13 mile bike ride, and a 3 mile run. ... and a 3 mile run. Heels & Wheels is sponsored by Mayo Clinic System ...
(Date:7/31/2015)... ... July 31, 2015 , ... Intellitec Solutions ... recent implementation of Microsoft Dynamics GP for a senior living facility in Maine. ... supporting senior living communities in 16 states. This further expansion was again a ...
Breaking Medicine News(10 mins):Health News:Congressional Health Caucus Founder Rep. Michael Burgess, MD, to Speak at RBMA Fall Educational Conference 2Health News:Congressional Health Caucus Founder Rep. Michael Burgess, MD, to Speak at RBMA Fall Educational Conference 3Health News:Make Less Mess while Cooking with Crack’em 2Health News:Testosterone Lawsuit News: Androgel Lawsuit Conference Held 2Health News:Testosterone Lawsuit News: Androgel Lawsuit Conference Held 3Health News:Testosterone Lawsuit News: Androgel Lawsuit Conference Held 4Health News:Heels & Wheels for Megan's House Set for Saturday August 22, 2015 in Waycross, Georgia 2Health News:Intellitec Solutions Expands Long term Care ERP Offerings to Maine 2
... ... state of today,s global biopharmaceutical environment. , ... Horsham, PA, USA (Vocus) June 5, 2009 -- ... biopharmaceutical industry,s largest and longest running global, multidisciplinary conference featuring sessions and preconference tutorials ...
... Conference Components , , BUFFALO, N.Y., June 5, ... 2009 Annual Conference will be held June 7-11 at ... This year,s conference will focus on priority public health ... A. , , "The 2009 conference theme, ,Evidence-based ...
... (June 4, 2009) -- For patients with the most common ... protease inhibitor called telaprevir to the current standard therapy can ... it in half the time of standard therapy alone. ... Duke Clinical Research Institute (DCRI) and 36 other sites, including ...
... , WASHINGTON, June 5 The American Society of ... its 2009 Minority Medical Student Award Program (MMSAP), which ... hematology research. Under the program, each award recipient will ... career development mentor, travel stipends to attend the ASH ...
... all patients who undergo myocardial infarction are experiencing onerous fatigue ... fatigued are those who perceive the infarction as a sign ... to control, and those who believe that the illness has ... of a thesis presented at the Sahlgrenska Academy, University of ...
... /PRNewswire-FirstCall/ -- NeoGenomics, Inc. (NASD OTC Bulletin ... the Fifth Annual Noble Financial Equity Conference at 9:15 ... Seminole Hard Rock Hotel in Hollywood, FL. Robert ... give a presentation regarding NeoGenomics, market positioning, financial performance, ...
Cached Medicine News:Health News:DIA 45th Annual Meeting Features Sessions Highlighting Wyeth v. Levine and Pandemic Influenza 2Health News:DIA 45th Annual Meeting Features Sessions Highlighting Wyeth v. Levine and Pandemic Influenza 3Health News:Council of State and Territorial Epidemiologists Annual Conference Begins June 7 in Buffalo, NY 2Health News:Council of State and Territorial Epidemiologists Annual Conference Begins June 7 in Buffalo, NY 3Health News:NEJM study points to new era in hepatitis C treatment 2Health News:NEJM study points to new era in hepatitis C treatment 3Health News:Minority Medical Students Receive Support to Pursue Hematology Research 2Health News:Minority Medical Students Receive Support to Pursue Hematology Research 3Health News:Fatigue common after myocardial infarction 2Health News:NeoGenomics to Present at Noble Financial's 5th Annual Equity Conference on Monday, June 8th 2
... of minor knee pain like arthritis, tendonitis ... with the motion of the knee, applying ... tendon and assisting in the relief of ... with high density foam padding molds itself ...
... Bariatric Knee Immobilizer is made of lightweight ... a breathable foam material that wicks moisture ... posterior aspect of the splint is uniquely ... The loop and lock closure straps allow ...
... brushed nylon, laminated to breathable foam. Three ... strap. Velcro straps with loop closures. Lightweight ... lateral stays., ,Available with optional hot ... Pad helps defeat the pain cycle by ...
... supports are a convenient, reusable, patient-friendly ... for common orthopedic conditions/instabilities. These products ... compression and lateral to medial influence ... the skin and soft tissue structures. ...
Medicine Products: